Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) shot up 0.6% on Thursday . The company traded as high as $3.69 and last traded at $3.65. 51,978 shares changed hands during trading, a decline of 57% from the average session volume of 120,239 shares. The stock had previously closed at $3.63.
Analysts Set New Price Targets
PSTV has been the topic of several research reports. Ascendiant Capital Markets cut their price target on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Plus Therapeutics currently has an average rating of “Hold” and a consensus target price of $56.40.
Get Our Latest Analysis on PSTV
Plus Therapeutics Stock Performance
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. As a group, analysts expect that Plus Therapeutics, Inc. will post -3.76 EPS for the current fiscal year.
Institutional Investors Weigh In On Plus Therapeutics
A number of large investors have recently modified their holdings of PSTV. Susquehanna International Group LLP purchased a new position in shares of Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics in the second quarter worth $41,000. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. XTX Topco Ltd acquired a new stake in shares of Plus Therapeutics during the fourth quarter worth $127,000. Finally, State Street Corp grew its holdings in shares of Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares during the last quarter. Hedge funds and other institutional investors own 3.28% of the company’s stock.
Plus Therapeutics Company Profile
Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.
The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.
Featured Stories
- Five stocks we like better than Plus Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
